Defining the implant treatment volume for patients with low risk prostate cancer: Does the anterior base need to be treated?

International Journal of Radiation Oncology Biology Physics

Volumn 43, Issue 3, 1999, Pages 587-590

  D'Amico, Anthony V ^a   Davis, Ann ^a   Vargas, Sara O ^b   Renshaw, Andrew A ^b   Jiroutek, Michael ^b   Richie, Jerome P ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Brachytherapy; Clinical stage; Gleason score; Prostate cancer; Prostate specific antigen; Treatment volume

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BRACHYTHERAPY; CANCER STAGING; CLINICAL ARTICLE; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME; TUMOR BIOPSY;

EID: 0032972089     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00434-9     Document Type: Article

References (23)

1. D'Amico A.V., Coleman C.N. The role of interstitial radiotherapy in the management of clinically organ confined prostate cancer The jury is still out . J Clin Oncol. 14:1996;304-315.
2. Wallner K., Roy J., Harrison L. Tumor control and morbidity following transperineal Iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol. 14:1996;449-453.
3. Blasko JC. 1998 Annual Meeting of the American Brachytherapy Society: "Defining the patient selection process for prostate brachytherapy." (personal communication).
4. Ragde H., Blasko J.C., Grimm P.D., et al. Interstitial Iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer. 80:1997;442-453.
5. Gelblum D.Y., Potters L., Ashley R., et al. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. (Abstr.) Int J Radiat Oncol Biol Phys. 42:1998;220.
6. McNeal J.E. Normal Histology of the Prostate. Am J Surg Pathol. 12:1988;619-633.
7. Gleason D.F. Histologic grading and staging of prostatic carcinoma. Tannenbaum M. Urologic pathology. 1977;171-187 Lea & Febiger, Philadelphia.
8. Beahrs O.H., Henson D.E., Hutter R.V.P. American Joint Committee on Cancer, Manual for staging cancer. 4th ed. 1997;JP Lippincott, Philadelphia.
9. Oesterling J.E., Jacobsen S.J., Klee G.G., et al. Free, complexed and total serum prostate specific antigen The establishment of appropriate reference ranges for their concentrations and ratios . J Urol. 154:1995;1090-1095.
10. Zagars G.K., Pollack A., Kavadi V.S., et al. Prostate specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 32:1995;293-306.
11. Pisansky T.M., Kahn M.J., Rasp G.M., et al. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate cancer. Cancer. 79:1997;337-344.
12. Lee W.R., Hanks G.E., Schultheiss T.E., et al. Localized prostate cancer treated by external beam radiotherapy alone: Serum prostate specific antigen driven outcome analysis. J Clin Oncol. 13:1995;464-469.
13. Pisansky T.M., Cha S.S., Earle J.D., et al. Prostate specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol. 11:1993;2158-2166.
14. Zietman A.L., Coen J.J., Shipley W.U., et al. Radical radiation therapy in the management of prostatic adenocarcinoma: The initial prostate specific antigen value as a predictor of treatment outcome. J Urol. 151:1994;640-645.
15. Hanks G.E., Lee W.R., Schultheiss T.E. Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J Urol. 154:1995;456-459.
16. Partin A.W., Piantadosi S., Sanda M.G., et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology. 45:1995;831-838.
17. Lerner S.E., Blute M.L., Bergstralh E.J., et al. Analysis of risk factors for progression in patients with pathologically organ confined prostate cancers after radical retropubic prostatectomy. J Urol. 156:1996;137-143.
18. Zietman A.L., Edelstein R.A., Coen J.J., et al. Radical prostatectomy for adenocarcinoma of the prostate. The influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology. 43:1994;828-833.
19. D'Amico A.V., Whittington R., Malkowicz S.B., et al. PSA failure despite pathologically organ confined and margin negative disease The basis for an adjuvant therapy trial . J Clin Oncol. 15:1997;1465-1469.
20. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Outcome based staging for clinically localized adenocarcinoma of the prostate. J Urol. 158:1997;1422-1426.
21. Blasko J.C., Wallner K., Grimm P.D., et al. Prostate specific antigen based disease control following ultrasound guided I 125 implantation for stage T1/T2 prostatic carcinoma. J Urol. 154:1995;1096-1099.
22. Sheskin D. Handbook of parametric and non-parametric procedures. 1997;CRC Press, Boca Raton.
23. McNeal J.E., Redwine E.A., Freiha F.S., et al. Zonal distribution of prostatic adenocarcinoma Correlation with histologic pattern and direction of spread . Am J Surg Pathol. 12:1988;897-906.